GeneMachines Raises Over $10 Million in Private Financing
Source: Gene Machines
<%=company1%> (San Carlos, CA), a developer of automated genomics instrumentation for the life sciences industry, has closed a $10.7 million Series B preferred stock financing. Oxford Bioscience Partners III L.P. (Boston) and Frazier & Co. (Seattle) each invested $5 million, and other private investors contributed the additional financing. Genemachines will use the proceeds to scale up the its sales and marketing programs, manufacturing capabilities, and product development.Edited by Jim Pomager
As part of the financing, Martin Vogelbaum, general partner of Oxford Bioscience Partners III L.P., and Robert Overell, general partner of Frazier & Co., were elected to GeneMachine's board of directors.
GeneMachines develops and provides automated instrumentation for life sciences researchers. The company is currently developing GeneSuite, a product line of integrated instruments, reagents, and consumables for DNA sample preparation and functional analysis.
For more information: Scott Hunicke-Smith, CEO, GeneMachines, 935 Washington St., San Carlos, CA 94070. Tel: 650-508-1634. Fax: 650-508-1644.